Rheumatoid Arthritis
Conditions
Keywords
Mulligan Mobilization, Hand Rheumatoid Arthritis
Brief summary
The goal of this randomized-controlled study is to learn about the effectiveness of the Mulligan mobilization in rheumatoid hands. The main question it aims to answer are: -Does mulligan mobilization reduce effusion in wrist joints with rheumatoid arthritis? Participants will take Mulligan mobilization application and active ROM exercises for their hands. Researcher will compare treatments group ith sham mobilization.
Detailed description
Rheumatoid arthritis (RA) is a systemic disease that can lead to chronic pain, bone and soft tissue damage, and disability retirement. Alleviating pain and maintaining joint range of motion in RA are important for reducing disability. Joint mobilizations are manual therapy techniques used to increase range of motion and reduce pain. The aim of this study is to investigate the effects of rheumatoid hand exercise and protective approach and joint mobilization applications on pain, functional status and quality of life.
Interventions
OTHERMulligan Mobilization
Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.
Sponsors
Kirsehir Ahi Evran Universitesi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Having been diagnosed with RAS according to ACR and EULAR criteria, * Being under the control of a physiatrist for at least 1 year, * Have not had any upper extremity surgery in the last 6 months * Have the cognitive capacity to understand commands, * Not to be involved in any other rehabilitation program or study,
Exclusion criteria
* Presence of soft tissue injury and chronic bone damage in the hand, * Presence of acute inflammation in any joint in the previous week, * Presence of a degenerative or non-degenerative neurological condition that causes a change in pain perception,
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Joint activity | 6 weeks | Primary outcomes included the automated quantification (Q) of joint activity using color Doppler pixel count calculations (% hyperemia/blood flow activity score within an inflamed joint: color Q-Doppler MCP/region) |
| Amount of hypertrophia and effusion in wrist joints | 6 weeks | Synovial fluid (area of hypertrophy and effusion, mm2: synovial fluid MCP/region) |
| Distance in wrist joints | 6 weeks | the radiographic distance (mm) between the MCP or interphalangeal bone space (joint space MCP/region) |
| DAS-28 | 6 weeks | High disease activ ity \>5.1, low disease activity ≤ 3.2, remission ≤ 2.6 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determining the state of pain after treatment | 6 weeks | Pain will be assessed using the Mcgill-Melzack Pain Questionnaire |
| Physical, social, and emotional well-being in RA | 6 weeks | Arthritis Impact Measurement Scales (AIMS) |
| Grip force | 6 weeks | Hand grip strength will be measured with a pinch meter and a dynamometer |
| Range of Motion | 6 weeks | Range of Motion will be measured with goniometer |
| Post-treatment status of disease-related quality of life | 6 weeks | Quality of life was assessed using the Rheumatoid Arthritis Quality of Life (RAQoL). |
Countries
Turkey (Türkiye)
Outcome results
None listed